offline
Bristol-Myers Squibb agrees to acquire Celgene for about $74 Billion
The combined company will have nine products with more than $1 billion each in annual sales
...
Overall, the merged company will have nine products with more than $1 billion each in annual sales—most notably Celgene’s multiple myeloma drug Revlimid, which had $7.1 billion in sales through the first nine months of 2018, and Bristol’s lung-cancer treatment Opdivo, which had $4.9 billion over that same period.
The companies said Wednesday that their pipeline includes six expected near-term product launches representing more than $15 billion in revenue potential.
...
https://www.marketwatch.com/story/bristo...2019-01-03
![[Bild: CELGc1dl1659.png]](https://finviz.com/publish/010319/CELGc1dl1659.png)
The combined company will have nine products with more than $1 billion each in annual sales
...
Overall, the merged company will have nine products with more than $1 billion each in annual sales—most notably Celgene’s multiple myeloma drug Revlimid, which had $7.1 billion in sales through the first nine months of 2018, and Bristol’s lung-cancer treatment Opdivo, which had $4.9 billion over that same period.
The companies said Wednesday that their pipeline includes six expected near-term product launches representing more than $15 billion in revenue potential.
...
https://www.marketwatch.com/story/bristo...2019-01-03
